Multiple Sclerosis Drugs - Bosnia and Herzegovina

Bosnia and Herzegovina

The Multiple Sclerosis Drugs market in Bosnia and Herzegovina is expected to witness a significant increase in revenue, reaching US$2.99m by the year 2024.
Furthermore, it is projected that the market will continue to grow at a steady pace, with an annual growth rate (CAGR 2024-2029) of 0.98%.
This growth trajectory is expected to result in a market volume of US$3.14m by the year 2029.
When compared globally, United States is anticipated to generate the highest revenue in the Multiple Sclerosis Drugs market, with an estimated value of US$11,770.00m in 2024.
Bosnia and Herzegovina is experiencing a growing demand for innovative Multiple Sclerosis Drugs to address the needs of its population.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Multiple Sclerosis Drugs in Bosnia and Herzegovina has been increasing steadily in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Bosnia and Herzegovina prefer drugs that have fewer side effects, are easy to administer, and are affordable. They also prefer drugs that can help reduce the frequency and severity of relapses.

Trends in the market: The Multiple Sclerosis Drugs market in Bosnia and Herzegovina is growing due to the increasing prevalence of the disease. The country has one of the highest rates of Multiple Sclerosis in Europe. This has led to an increase in demand for drugs that can effectively treat the disease. In addition, the government has been investing in healthcare infrastructure, which has made it easier for patients to access treatment. The market is also witnessing a trend towards the development of new and more effective drugs.

Local special circumstances: Bosnia and Herzegovina is a lower-middle-income country with a relatively small healthcare budget. This has made it difficult for the government to provide adequate healthcare services to the population. As a result, many patients have to pay for their treatment out of pocket. This has led to a demand for affordable drugs that are still effective in treating the disease.

Underlying macroeconomic factors: The economy of Bosnia and Herzegovina has been growing steadily in recent years, which has led to an increase in healthcare spending. However, the country still faces many challenges, including high levels of unemployment and poverty. These factors have made it difficult for many patients to afford the high cost of Multiple Sclerosis Drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.